Economic impact of generic antiretrovirals in France for HIV patients' care: a simulation between 2019 and 2023.

ABSTRACT:

Background

In a context where the economic burden of HIV is increasing as HIV patients now have a close to normal lifespan, the availability of generic antiretrovirals commonly prescribed in 2017 and the imminence of patent expiration are expected to provide substantial savings in the coming years. This article aims to assess the economic impact of these generic antiretrovirals in France and specifically over a five-year period.

Methods

An agent-based model was developed to simulate patient trajectories and treatment use over a five-year period. By comparing the results of costs for trajectories simulated under different predefined scenarios, a budget impact model can be created and sensitivity analyses performed on several parameters of importance.

Results

The potent

SUBMITTER: Demeulemeester R 

PROVIDER: S-EPMC9044646 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature